Pleas for compassionate use access are on the increase, and Change.org is giving patients an audience.
Pleas for compassionate use access are on the increase, and Change.org is giving patients an audience. In PharmExec’s latest cover story - The Active Patient: Faces of Change by Ben Comer, Brianna Cayo-Cotter, Change.org’s managing director of communications, says one successful petition often begets another. Politicians and celebrities, in unprecedented fashion, are coming out in support of compassionate use petitions.
“We call it wildfire,” says Cayo-Cotter. “When one person starts a petition for access to a drug, you’ll start to see dozens and dozens of petitions…that ends up creating a space for there to be a real policy change, or an industry shift around an issue.”
Like the AIDS activist groups ACT UP and TAG, and their impact on US compassionate use policy in the 1980s, Change.org is in a position to push regulators and the drug industry to rethink issues that separate the medical establishment from its patients.
“Anybody can use Change.org,” says Cayo-Cotter. “It can raise a patient’s profile in a way that was impossible even three years ago.”
Patient advocacy groups are expanding beyond the traditional boundaries and roles that used to separate individual players in the healthcare system. There’s no commodity more valuable than human health. Expect patient advocacy efforts to continue expanding into areas including R&D, healthcare delivery and global access policy.
Other patient advocates profiled in The Active Patient: Faces of Change include Camila Strassle, an advocate working with the Cystic Fibrosis Foundation; Susan Grant, a patient and filmmaker promoting public awareness of frontotemporal dementia; and Sarah Krug, executive director at Cancer101, an organization that provides education to cancer patients based on individual needs.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.